ArticleVeterinary medicine and science2025
Topical Mitomycin C Application Following Surgical Excision in Canine Oral Papilloma: A Case Report.
Article in Veterinary medicine and science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Canine oral papillomatosis, caused by canine papilloma virus 1, is a benign condition primarily affecting young or immunosuppressed dogs. While most cases regress spontaneously, severe cases often require surgical intervention due to extensive lesions and associated discomforts. However, surgical excision is associated with a high risk of recurrence, necessitating adjuvant therapies. This report presents the case of a 1-year-old German Shepherd with severe oral papilloma unresponsive to prior treatments, managed through surgical excision followed by topical mitomycin C (MMC) application. MMC, applied intraoperatively and during follow-up, effectively prevented recurrence over a 1-year period. This case demonstrates the potential of MMC as an effective adjuvant therapy for severe canine oral papillomatosis, providing a novel approach in veterinary medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.